LIT-927   Click here for help

GtoPdb Ligand ID: 10075

Synonyms: compound 57 [PMID: 30106292]
Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: LIT-927 is a small molecule that binds to and neutralises the chemokine CXCL12 [1]. It has been termed a 'neutraligand'. LIT-927 was developed as an alternative strategy to inhibitors for CXCL12's cognate receptors CXCR4 or CXCR7, as a potential anti-inflammatory agent.
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 2
Hydrogen bond donors 2
Rotatable bonds 3
Topological polar surface area 75.21
Molecular weight 328.06
XLogP 4.27
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES COc1cc(ccc1O)c1[nH]c(=O)nc(c1)c1ccc(cc1)Cl
Isomeric SMILES COc1cc(ccc1O)c1[nH]c(=O)nc(c1)c1ccc(cc1)Cl
InChI InChI=1S/C17H13ClN2O3/c1-23-16-8-11(4-7-15(16)21)14-9-13(19-17(22)20-14)10-2-5-12(18)6-3-10/h2-9,21H,1H3,(H,19,20,22)
InChI Key BYYRNPIGDRRGLJ-UHFFFAOYSA-N
Immunopharmacology Comments
LIT-927 exhibits high binding selectivity for CXCL12 over other chemokines. Orally delivered LIT-927 reduces eosinophil recruitment in a murine model of allergic airway hypereosinophilia, indicating potential efficacy as an anti-asthmatic agent [1]. It offers a pharmacological tool that is suitable for the investigation of CXCL12 physiology in vivo and for further exploration of the utility/efficacy of chemokine neutralisation as a pharmacological strategy in inflammatory and related diseases.